Outlook Therapeutics (NASDAQ:OTLK) Upgraded by BTIG Research to “Buy”

BTIG Research upgraded shares of Outlook Therapeutics (NASDAQ:OTLK) from a neutral rating to a buy rating in a research note published on Wednesday, MarketBeat Ratings reports. BTIG Research currently has $50.00 price objective on the stock.

OTLK has been the topic of a number of other reports. HC Wainwright boosted their price objective on Outlook Therapeutics to $30.00 and gave the company a buy rating in a research report on Monday. Chardan Capital raised shares of Outlook Therapeutics from a neutral rating to a buy rating and set a $60.00 price target on the stock in a report on Thursday, February 15th. Capital One Financial reaffirmed an overweight rating on shares of Outlook Therapeutics in a report on Friday, February 16th. Ascendiant Capital Markets upped their target price on shares of Outlook Therapeutics from $30.00 to $40.00 and gave the company a buy rating in a research note on Friday, December 29th. Finally, Brookline Capital Management upgraded shares of Outlook Therapeutics from a hold rating to a buy rating and set a $31.40 price target for the company in a research note on Thursday, January 25th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Outlook Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $46.43.

Outlook Therapeutics Price Performance

Shares of Outlook Therapeutics stock opened at $9.37 on Wednesday. The company has a market cap of $121.90 million and a PE ratio of -2.34. The firm has a fifty day moving average price of $8.12 and a two-hundred day moving average price of $7.84. Outlook Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $40.60.

Outlook Therapeutics (NASDAQ:OTLK) last released its earnings results on Wednesday, February 14th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.20. Analysts expect that Outlook Therapeutics will post -3.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in Outlook Therapeutics by 55.1% during the 1st quarter. JPMorgan Chase & Co. now owns 53,465 shares of the company’s stock worth $95,000 after acquiring an additional 18,989 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Outlook Therapeutics by 14.3% during the first quarter. Bank of New York Mellon Corp now owns 332,411 shares of the company’s stock worth $592,000 after acquiring an additional 41,606 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Outlook Therapeutics by 93.3% during the first quarter. Rhumbline Advisers now owns 92,634 shares of the company’s stock valued at $165,000 after acquiring an additional 44,704 shares during the period. BlackRock Inc. boosted its holdings in Outlook Therapeutics by 12.9% in the first quarter. BlackRock Inc. now owns 6,680,116 shares of the company’s stock valued at $11,891,000 after acquiring an additional 761,356 shares during the last quarter. Finally, American International Group Inc. increased its position in Outlook Therapeutics by 19.5% in the first quarter. American International Group Inc. now owns 56,554 shares of the company’s stock worth $101,000 after purchasing an additional 9,225 shares during the period. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.